Kaposi's sarcoma-associated herpesvirus (KSHV) naturally infects humans, and over 95% of healthy persons have no symptoms. KSHV causes three types of malignancies in immunosuppressed patients: Kaposi's sarcoma, body cavity-based lymphoma, and multicentric Castleman's disease (1-3). KSHV establishes a latent infection in most infected cells, whereas a small proportion of cells develop lytic infection. The genetic profiles of KSHV-infected populations differ from those of uninfected populations, with host cell transcriptional remodeling observed in latently KSHV-infected cells (4) and global mRNA shutoff noted during lytic replication (5, 6).A limited number of viral transcripts appear in the latent stage, whereas the viral genome produces all of the viral transcripts during the lytic phase (7). A key viral replication and transcription activator (RTA) switches latent infection to lytic replication (8). Studies have characterized multiple cellular signaling pathways and transcription factors required for RTA expression. Mitogenactivated stimuli or stresses initiate RTA expression through mitogen-activated protein kinase (MAPK) or stress-activated protein kinases (SAPK), respectively (9-14). Thereafter, RTA activates viral lytic transcription and replication. RTA binding sites in the KSHV genome and responsive KSHV promoters have been characterized (15,16); these studies revealed that most viral gene expression is not directly activated by RTA and requires additional cellular transcription factors. Based on the analysis of elements in the RTA, ORF45, and K8 promoters, multiple transcription factors, including c-Fos, c-Jun, Sp1, CREB, C/EBP, c-Myc, and ATF-2, are required for the expression of immediate early (IE) genes (11)(12)(13)(17)(18)(19); most of these transcription factors are the direct or indirect targets of MAPK pathways (20,21). Recently, nonconventional viral DNA elements, viral noncoding RNA, and viral proteins required for KSHV late transcription have been characterized (22)(23)(24)(25)(26). The viral lytic proteins ORF24, ORF31, and ORF34 assemble into a transcriptional activator complex (25), and ORF24 recruits RNA polymerase II to viral late promot-